专题：Advanced Breast Cancer Therapies

This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.
最新文献
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex

Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)

article Full Text OpenAlex

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity

preprint Full Text OpenAlex

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer

article Full Text OpenAlex

Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models

article Full Text OpenAlex

Breast cancer promotes the expression of neurotransmitter receptor related gene groups and image simulation of prognosis model

article Full Text OpenAlex

Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers

article Full Text OpenAlex

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

article Full Text OpenAlex

First voltammetric studies, spectrophotometric and molecular docking investigations of the interaction of an anticancer drug ribociclib-DNA and analytical applications of disposable pencil graphite sensor

article Full Text OpenAlex

432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04

article Full Text OpenAlex

近5年高被引文献
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

article Full Text OpenAlex 2161 FWCI322.65752968

Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review

review Full Text OpenAlex 1558 FWCI110.1841557

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

review Full Text OpenAlex 1438 FWCI111.96003515

Breast cancer

review Full Text OpenAlex 1433 FWCI207.1185657

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

review Full Text OpenAlex 1396 FWCI259.56722987

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

review Full Text OpenAlex 1331 FWCI199.3147621

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

article Full Text OpenAlex 1301 FWCI100.32373936

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

article Full Text OpenAlex 1154 FWCI145.38980445

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 904 FWCI117.46642972

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

review Full Text OpenAlex 727 FWCI62.56580934